Centinel Spine, LLC appears in FDA device records as the applicant behind the prodisc cervical disc replacement line and its associated instrumentation. The supplied filings span a 2007 original premarket approval, a 2026 approval of a labeling supplement expanding indications for prodisc C Nova, and a 2026 510(k) clearance for manual instruments used with total disc replacement devices. The records identify the applicant and the named devices; they do not establish corporate ownership beyond the applicant name, nor do they document commercial availability, clinical outcomes or facility counts. [1][2][3]
The prodisc C cervical disc line
The original approval, P070001, covers the PRODISC TM-C TOTAL DISC REPLACEMENT, a class 3 intervertebral disc prosthesis under product code MJO, decided December 17, 2007. The approval order describes implantation via an open anterior approach and lists the device under the orthopedic advisory committee. Later records use the prodisc C styling for the same product family, including prodisc C Nova and prodisc C SK and prodisc C Vivo. [3][2][7]
A Summary of Safety and Effectiveness Data for P070001/S025 names prodisc C SK and prodisc C Vivo as artificial cervical discs under product code MJO, with Centinel Spine, LLC at 900 Airport Road, Suite 3B, West Chester, PA 19380 as the applicant address. That address is a filing address in the FDA records, not a verified headquarters designation. [7]
2026 labeling supplement for prodisc C Nova
Supplement P070001/S031 for prodisc C Nova was received May 12, 2026 and approved September 9, 2026 under the normal 180-day track. The approval order states that the supplement requested expansion of the indications from one-level use to two-level use, and the supplement reason is recorded as a labeling change covering indications, instructions, shelf life or tradename. [2]
The supplement is a change to the original P070001 approval rather than a separate PMA, and FDA's PMA page notes that a supplement may have altered the device description or indication from the original approval. The one-level indication described on Centinel Spine's prodisc C page reflects the company's own published statement and predates the 2026 supplement in the public information. [5][8][2]
Instrument 510(k) K263159
K263159 was received September 9, 2026 and decided October 7, 2026 with a substantially equivalent decision under the special clearance type. The device name lists prodisc C, prodisc C SK, prodisc C Nova and prodisc C Vivo Instruments, and FDA classifies the record as manual instruments designed for use with total disc replacement devices, class 2, regulation 888.4515, product code QLQ. The clearance therefore covers the instruments associated with the implants, not the implants themselves. [1]
Centinel Spine publishes a surgical technique guide for its cervical total disc replacement system describing use with the pro disc Cervical Gen2 Instrument Set and a gold instrument case with light gray corners. The guide lists sections for patient positioning, exposure, discectomy and decompression, implant selection and implantation steps. [6]
Published labeling and company statements
Centinel Spine's guides page lists a U.S.-only prodisc C Vivo instructions-for-use revision dated September 2026, with archived U.S. versions from October 2025 and August 2022, and international prodisc C Vivo versions including a November 2025 revision. A separate prodisc C Nova instructions-for-use document is labeled for markets outside the U.S. and points readers to EUDAMED for its summary of safety and clinical performance. [9][10]
On its prodisc C page, Centinel Spine states that the prodisc C design began clinical use in 1990 and cites over 300,000 device implantations worldwide and more than 590 published papers; the page also states that prodisc C is indicated and FDA-approved for one-level use in the U.S. These are the company's own published claims, attributed here to their publisher rather than verified independently. [8]
